Kiniksa Pharmaceuticals (KNSA) Competitors $26.12 -0.58 (-2.17%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$26.40 +0.28 (+1.07%) As of 05/21/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KNSA vs. ROIV, RVMD, ELAN, BPMC, BBIO, VRNA, TLX, TGTX, GRFS, and LNTHShould you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma (VRNA), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), Grifols (GRFS), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Kiniksa Pharmaceuticals vs. Roivant Sciences Revolution Medicines Elanco Animal Health Blueprint Medicines BridgeBio Pharma Verona Pharma Telix Pharmaceuticals Limited American Depositary Shares TG Therapeutics Grifols Lantheus Roivant Sciences (NASDAQ:ROIV) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership. Which has better valuation & earnings, ROIV or KNSA? Roivant Sciences has higher earnings, but lower revenue than Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$122.59M63.51$4.35B-$0.15-72.73Kiniksa Pharmaceuticals$481.17M3.96$14.08M-$0.25-104.48 Do insiders & institutionals have more ownership in ROIV or KNSA? 64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, ROIV or KNSA? Roivant Sciences has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500. Is ROIV or KNSA more profitable? Kiniksa Pharmaceuticals has a net margin of -2.36% compared to Roivant Sciences' net margin of -119.54%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences-119.54% -14.05% -12.81% Kiniksa Pharmaceuticals -2.36%-7.31%-5.95% Does the media refer more to ROIV or KNSA? In the previous week, Roivant Sciences had 5 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 15 mentions for Roivant Sciences and 10 mentions for Kiniksa Pharmaceuticals. Roivant Sciences' average media sentiment score of 1.47 beat Kiniksa Pharmaceuticals' score of 1.38 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 12 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kiniksa Pharmaceuticals 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer ROIV or KNSA? Kiniksa Pharmaceuticals received 120 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.57% of users gave Roivant Sciences an outperform vote while only 65.54% of users gave Kiniksa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5578.57% Underperform Votes1521.43% Kiniksa PharmaceuticalsOutperform Votes17565.54% Underperform Votes9234.46% Do analysts recommend ROIV or KNSA? Roivant Sciences presently has a consensus target price of $17.50, indicating a potential upside of 60.40%. Kiniksa Pharmaceuticals has a consensus target price of $38.80, indicating a potential upside of 48.55%. Given Roivant Sciences' higher probable upside, research analysts clearly believe Roivant Sciences is more favorable than Kiniksa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryRoivant Sciences beats Kiniksa Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Kiniksa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KNSA vs. The Competition Export to ExcelMetricKiniksa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.91B$6.52B$5.37B$8.39BDividend YieldN/A2.65%5.22%4.10%P/E Ratio-186.568.9226.8419.71Price / Sales3.96253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book4.196.466.794.50Net Income$14.08M$143.98M$3.23B$248.18M7 Day Performance0.97%2.03%1.53%0.20%1 Month Performance30.47%4.11%10.06%12.37%1 Year Performance35.55%-2.87%16.72%7.04% Kiniksa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KNSAKiniksa Pharmaceuticals2.9567 of 5 stars$26.12-2.2%$38.80+48.5%+34.8%$1.91B$481.17M-186.56220Positive NewsInsider TradeROIVRoivant Sciences2.1398 of 5 stars$10.84+0.5%$17.50+61.4%-2.8%$7.73B$122.59M-72.26860Positive NewsUpcoming EarningsRVMDRevolution Medicines4.3654 of 5 stars$39.93+1.0%$67.08+68.0%-2.3%$7.44B$742,000.00-11.12250Positive NewsELANElanco Animal Health3.2136 of 5 stars$13.24+2.5%$15.17+14.6%-24.4%$6.58B$4.43B33.109,800Analyst ForecastGap UpBPMCBlueprint Medicines1.7878 of 5 stars$101.21-0.5%$126.56+25.0%-2.0%$6.54B$562.12M-93.71640Positive NewsInsider TradeBBIOBridgeBio Pharma4.5948 of 5 stars$33.69-0.4%$57.09+69.5%+12.2%$6.40B$127.42M-11.82400Positive NewsInsider TradeVRNAVerona Pharma2.6686 of 5 stars$72.58+1.8%$81.50+12.3%+492.7%$5.88B$118.54M-37.8030Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.54-0.8%$22.00+33.0%N/A$5.59B$783.21M0.00N/AGap DownTGTXTG Therapeutics3.8269 of 5 stars$34.98+1.8%$40.80+16.6%+106.0%$5.55B$386.39M-349.77290GRFSGrifols3.1975 of 5 stars$8.00+3.1%N/A+6.8%$5.50B$7.21B6.8426,300Positive NewsLNTHLantheus4.4469 of 5 stars$78.25-3.7%$132.67+69.5%-6.9%$5.41B$1.54B13.02700 Related Companies and Tools Related Companies Roivant Sciences Alternatives Revolution Medicines Alternatives Elanco Animal Health Alternatives Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Verona Pharma Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives TG Therapeutics Alternatives Grifols Alternatives Lantheus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KNSA) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiniksa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KNSA Stock Free KNSA Stock Alerts